NCT01258998 · REGISTRY CONDITION SEARCH

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2020-11-04

This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response Rate (ORR)

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Participants With Change in Cytokine Levels With p Values <0.05

→

outcome · POSTED

Number of Participants With Change in Chemokine Levels With p Values <0.05

→

outcome · POSTED

Number of Participants With Change in Biomarker Levels With p Values <0.05

→

outcome · POSTED

Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically confirmed Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (small lymphocytic lymphoma may be included) * Relapsed or refractory after at least one regimen and with no curative option with conventional therapy * Bidimensionally measurable disease (at least 2 cm) * No evidence of cerebral or meningeal involvement by lymphoma * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Signed informed consent form prior to enrollment * Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately Exclusion Criteria: * Burkitt's lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia and cutaneous T-cell lymphoma * Chemotherapy or radiation therapy or other investigational agents within 3 weeks prior to entering the study unless there is clear evidence of progression of disease and toxicity from previous treatment has resolved in which case study entry may be within 1 week of last treatment * Previous radioimmunotherapy within 12 weeks * Patients with known immunodeficiency virus (HIV) infection must not have cluster of differentiation (CD)4 cells \< 400/mm\^3 and who must not have a prior acquired immunodeficiency syndrome (AIDS)-defining diagnosis and cannot be on antiretroviral therapy for HIV * Known active viral hepatitis * Any serious active disease or co-morbid condition, which in the opinion of the principal investigator, will interfere with the safety or with compliance with the study * Absolute neutrophil count \< 1.5 x 10\^9/L * Platelets \< 75 x 10\^9/L * Total bilirubin \> 1.5 x upper limit of normal (ULN) (\> 3 x ULN for patients with liver involvement) * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \> 2.5 x ULN (\> 5 x ULN for patients with liver involvement) * Serum creatinine \> 2 x ULN * Hemoglobin (Hb)A1C \> 8% * Patients receiving any medications or substances that are inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP 450 3A4) are ineligible * Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK-2206, but the hyperglycemia should be well controlled on oral agents before the patient enters the trial * Cardiovascular: baseline Fredericia corrected QT interval (QTcF) \> 450 msec (male) or QTcF \> 470 msec (female) will exclude patients from entry on study * Significant heart block or baseline bradycardia \< 50 beats per minute (bpm) due to cardiac disease * Patients who are pregnant or breastfeeding
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: Akt inhibitor MK2206
Other: laboratory biomarker analysis
label
Treatment (Akt inhibitor MK2206)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (Akt inhibitor MK2206)
description
Given PO
name
Akt inhibitor MK2206
other Names
MK2206
type
DRUG
arm Group Labels
Treatment (Akt inhibitor MK2206)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 60
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Complete Response (CR) Disappearance of all evidence of disease(a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT Not palpable, nodules disappeared Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immuno histochemistry should be negative. Partial Response (PR) Regression of measurable disease and no new sites, 50% decrease in , sum of the product of the diameters SPD of up to 6 largest dominant masses; no increase in size of other nodes(a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT, 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen, Irrelevant if positive prior to therapy; cell type should be specified.
measure
Objective Response Rate (ORR)
time Frame
4 months

secondary Outcomes

description
Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.
measure
Progression-free Survival
time Frame
From treatment start date until the date of first documented progression or date of death from any cause, whichever came first.
description
Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.
measure
Duration of Response
time Frame
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.
description
Number of surviving participants without disease progression or death for any reason at one year post treatment. Kaplan-Meier method was used.
measure
Overall Survival
time Frame
From the start of treatment to death or 30 days after removal from the study whichever occurs first
description
The changes in the cytokine levels from baseline analyzed by Wilcoxon signed rank test. P values \< 0.05 were considered statistically significant.
measure
Number of Participants With Change in Cytokine Levels With p Values <0.05
time Frame
Baseline to up to 30 days post-treatment
description
The changes in the chemokine levels from baseline analyzed by Wilcoxon signed rank test. P values \< 0.05 were considered statistically significant.
measure
Number of Participants With Change in Chemokine Levels With p Values <0.05
time Frame
Baseline to up to 30 days post-treatment
description
The changes in the cytokine levels from baseline analyzed by Wilcoxon signed rank test. P values \< 0.05 were considered statistically significant.
measure
Number of Participants With Change in Biomarker Levels With p Values <0.05
time Frame
Baseline to up to 30 days post-treatment
description
Toxicity data will be summarized by frequency tables.
measure
Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
time Frame
Up to 30 days

Full study description

brief Summary: This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
detailed Description: PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) of MK-2206 (Akt inhibitor MK2206) in patients with relapsed/refractory lymphoma. SECONDARY OBJECTIVES: I. Assess the progression free survival (PFS) of MK-2206 in patients with relapsed/refractory lymphoma. II. Assess the safety and tolerability of MK-2206 monotherapy. III. Examine pretreatment phosphorylated v-akt murine thymoma viral oncogene homolog 1 (pAkt) protein expression by immunohistochemistry, and correlate the results with treatment response. IV. Examine the effect of therapy on serum cytokines and chemokines that regulate the tumor-promoting inflammatory process and/or immunity in patients with relapsed/refractory lymphoma, and correlate the results with treatment response. OUTLINE: Patients receive Akt inhibitor MK2206 orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.

Source references

references

citation
Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov;171(4):463-70. doi: 10.1111/bjh.13603. Epub 2015 Jul 27.
pmid
26213141
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2425d196e9cb0cae4c53
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
payload sha256
62dca2452c1d272c397fec7f0e3776d0bb6dde16885fe86d392b883eb3d456a2
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2425d196e9cb0cae4c53
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Peripheral T-Cell Non-Hodgkin Lymphoma
query disease state id
ds-peripheral-t-cell-non-hodgkin-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
source file sha256
e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
source json pointer
/studies/94/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Peripheral+T-Cell+Non-Hodgkin+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-40e7fe735a86cbf58882
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
payload sha256
74272f955a67aa07d955568e1019da065e35c33a8e8c41d793e559ed548b7b83
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-40e7fe735a86cbf58882
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Hairy Cell Leukemia
query disease state id
ds-hairy-cell-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
source json pointer
/studies/34/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-4fc85dbccad577ac013c
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
payload sha256
3aa68a447f8298debb81d2c75ce4ac56df1f229b4e18fc9130407ac5e99a89ad
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-4fc85dbccad577ac013c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Acute Undifferentiated Leukemia
query disease state id
ds-acute-undifferentiated-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
source json pointer
/studies/41/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-80fb0a76a8403f15f739
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
payload sha256
e8f552e0d445819b7a012c0c2523882ec556ead41edf908397986b1d3d5f9026
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-80fb0a76a8403f15f739
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Small Intestine Cancer
query disease state id
ds-small-intestine-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
source json pointer
/studies/80/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-9f9566ae5353a432097a
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
b35419b3f16262b4c12b81f379a95778d09b63ab951423a689a30388647585bb
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-9f9566ae5353a432097a
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/743/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b4a1edd67b90feefde99
requested nct id
NCT01258998
primary nct id
NCT01258998
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
payload sha256
8b7fbbda198d21ebfa33e2905bd050221de95592b9a20ee6e8be7d4bb34bfc8a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b4a1edd67b90feefde99
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01258998
occurrences
context exact
NCT01258998
end
11
exact text
NCT01258998
start
0
offset unit
unicode_code_points
query cond
Testicular Cancer
query disease state id
ds-testicular-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
source json pointer
/studies/39/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
ed6a858fa96d27bde29e8942c96d574e6ed3c12ac3e05587b751cc76daf4910c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice